Compositions and use of varenicline for treating dry eye
Described herein are methods and pharmaceutical formulations for treating dry eye disease.
1. A method of treating dry eye in a human, comprising nasally administering between 5 micrograms and 1000 micrograms of varenicline per day, wherein varenicline is in a liquid pharmaceutical formulation comprising a concentration of varenicline between about 0.1 mg/mL and about 10 mg/mL.
2. The method of claim 1 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.2 mg/mL and 1 mg/mL.
3. The method of claim 1 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.5 mg/mL and 1 mg/mL.
4. The method of claim 1 , comprising nasally administering between 5 micrograms and 600 micrograms of varenicline per day.
5. The method of claim 4 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.2 mg/mL and 1 mg/mL.
6. The method of claim 4 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.5 mg/mL and 1 mg/mL.
7. The method of claim 6 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
8. The method of claim 7 , wherein the liquid pharmaceutical formulation does not include a preservative.
9. The method of claim 1 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
10. The method of claim 9 , wherein the liquid pharmaceutical formulation does not include a preservative.
11. The method of claim 4 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
12. The method of claim 11 , wherein the liquid pharmaceutical formulation does not include a preservative.
13. A method of treating dry eye in a human, comprising nasally administering between 5 micrograms and 100 micrograms of varenicline twice daily, wherein varenicline is in a liquid pharmaceutical formulation comprising a concentration of varenicline between about 0.1 mg/mL and about 10 mg/mL.
14. The method of claim 13 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.2 mg/mL and 1 mg/mL.
15. The method of claim 13 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.5 mg/mL and 1 mg/mL.
16. The method of claim 13 , comprising nasally administering between 25 micrograms and 100 micrograms of varenicline twice daily.
17. The method of claim 16 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.2 mg/mL and 1 mg/mL.
18. The method of claim 16 , wherein the liquid pharmaceutical formulation comprises a concentration of varenicline between 0.5 mg/mL and 1 mg/mL.
19. The method of claim 18 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
20. The method of claim 19 , wherein the liquid pharmaceutical formulation does not include a preservative.
21. The method of claim 13 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
22. The method of claim 21 , wherein the liquid pharmaceutical formulation does not include a preservative.
23. The method of claim 16 , wherein the liquid pharmaceutical formulation is administered as a nasal spray.
24. The method of claim 9 , wherein the liquid pharmaceutical formulation does not include a preservative.